secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azenta, Inc. (AZTA)
CIK:        0000933974
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001437749-24-034563
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azenta reports Q4 FY2024 revenue $170M; plans to sell B Medical; appoints Lawrence Lin CFO
--------------------------------------------------------------------------------

- FY2024 combined Sample Mgmt & Multiomics organic revenue grew 4%; Q4 organic growth 5%.
- Full year Adjusted EBITDA margin expanded ~300 bps to 7.5%; FY2025 guidance: 3-5% organic revenue growth and ~300 bps margin expansion.
- Board pursuing sale of B Medical Systems segment to simplify portfolio and focus on core businesses.
- Lawrence Lin appointed CFO effective after FY2024 10-K filing; Herman Cueto to serve as advisor through Q1 FY2025.
- Completed $1.5B share repurchase program, repurchasing 30M shares through September 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/933974/000143774924034563/0001437749-24-034563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/933974/000143774924034563/azta20240708_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-034563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer